Efficacy of vemurafenib (V), a selective <sup>V600E</sup>BRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.
Brian P. Higgins, Kenneth Kolinsky, Kathleen Schostack, Gideon Bollag, Richard J. Lee, Fei Su, Kathryn Packman